4//SEC Filing
Kjellson Nina S 4
Accession 0000950170-24-120198
CIK 0001863127other
Filed
Oct 31, 8:00 PM ET
Accepted
Nov 1, 6:18 PM ET
Size
35.8 KB
Accession
0000950170-24-120198
Insider Transaction Report
Form 4
Kjellson Nina S
Director
Transactions
- Sale
Common Stock
2024-10-30$16.17/sh−1,189$19,225→ 472,207 total(indirect: By 2020+ Co-Investment L.P. - Series 7) - Sale
Common Stock
2024-11-01$16.54/sh−23,938$396,040→ 3,813,378 total(indirect: By Canaan XI L.P.) - Sale
Common Stock
2024-11-01$16.54/sh−2,878$47,615→ 458,579 total(indirect: By 2020+ Co-Investment L.P. - Series 7) - Sale
Common Stock
2024-10-31$16.46/sh−89,390$1,471,324→ 3,837,316 total(indirect: By Canaan XI L.P.) - Sale
Common Stock
2024-10-31$16.46/sh−10,750$176,941→ 461,457 total(indirect: By 2020+ Co-Investment L.P. - Series 7) - Sale
Commmon Stock
2024-11-01$17.16/sh−604$10,364→ 3,812,774 total(indirect: By Canaan XI L.P.) - Sale
Common Stock
2024-11-01$17.16/sh−73$1,253→ 458,506 total(indirect: By 2020+ Co-Investment L.P. - Series 7) - Sale
Common Stock
2024-10-30$16.17/sh−9,889$159,895→ 3,926,706 total(indirect: By Canaan XI L.P.)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.66. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
- [F3]The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.00 to $16.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.10 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.13 to $17.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
Tyra Biosciences, Inc.
CIK 0001863127
Entity typeother
Related Parties
1- filerCIK 0001381980
Filing Metadata
- Form type
- 4
- Filed
- Oct 31, 8:00 PM ET
- Accepted
- Nov 1, 6:18 PM ET
- Size
- 35.8 KB